Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells

Molecular Immunology

Volumn 54, Issue 1, 2013, Pages 74-83

  Zheng, Yisheng ^a   Xu, Meng ^b   Li, Xiao ^b   Jia, Jinpeng ^b   Fan, Kexing ^c   Lai, Guoxiang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cimetidine; Myeloid derived suppressive cell; Tumor immune

Indexed keywords

ARGINASE 1; CASPASE; CD11B ANTIGEN; CIMETIDINE; FAMOTIDINE; FAS LIGAND; GAMMA INTERFERON; HISTAMINE H2 RECEPTOR; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD; BONE MARROW CELL; CANCER INHIBITION; CELL MIGRATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CIMETIDINE; DRUG EVALUATION, PRECLINICAL; HISTAMINE H2 ANTAGONISTS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MYELOID CELLS; MYELOID PROGENITOR CELLS;

ANIMALIA; MUS;

EID: 84872240349     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.10.035     Document Type: Article

References (39)

1. Adams W.J., Lawson J.A., Morris D.L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994, 35:1632-1636.
2. Adams W.J., Morris D.L., Ross W.R., Lubowski D.Z., King D.W. Cimetidine preserves non-specific immune function after colonic resection for cancer. Australian and New Zealand Journal of Surgery 1994, 64:847-852.
3. Bronte V., Serafini P., De Santo C., Marigo I., Tosello V., Mazzoni A., et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. Journal of Immunology 2003, 170:270-278.
4. Chornoguz O., Grmai L., Sinha P., Artemenko K.A., Zubarev R.A., Ostrand-Rosenberg S. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Molecular and Cellular Proteomics 2011, 10(3). M110.002980.
5. Freston J.W., Cimetidine I. Developments, pharmacology, and efficacy. Annals of Internal Medicine 1982, 97:573-580.
6. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 2009, 9(3):162-174.
7. Hellstrand K., Naredi P., Lindner P., Lundholm K., Rudenstam C.M., Hermodsson S., et al. Histamine in immunotherapy of advanced melanoma. Cancer Immunology, Immunotherapy: CII 1994, 39:416-419.
8. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Research 2006, 66(2):1123-1131.
9. Ko J.S., Zea A.H., Rini B.I., Ireland J.L., Elson P., Cohen P., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clinical Cancer Research 2009, 15(6):2148-2157.
10. Kubota T., Fujiwara H., Ueda Y., Itoh T., Yamashita T., Yoshimura T., et al. Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients. British Journal of Cancer 2002, 86:1257-1261.
11. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research 2003, 63:4441-4449.
12. Kusmartsev S., Nefedova Y., Yoder D., Gabrilovich D.I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. Journal of Immunology 2004, 172:989-999.
13. Kusmartsev S., Eruslanov E., Kübler H., Tseng T., Sakai Y., Su Z., et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. Journal of Immunology 2008, 181:346-353.
14. Lawson J.A., Adams W.J., Morris D.L. Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. British Journal of Cancer 1996, 73:872-876.
15. Le H.K., Graham L., Cha E., Morales J.K., Manjili M.H., Bear H.D. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. International Immunopharmacology 2009, 9(7-8):900-909.
16. Leite-de-Moraes M.C., Herbelin A., Gouarin C., Koezuka Y., Schneider E., Dy M. Fas/Fas Ligand Interactions Promote Activation-Induced Cell Death of NK T Lymphocytes. Journal of Immunology 2000, 165(8):4367-4371.
17. Marshall M.E., Riley L.K., Rhoades J., Eichhorn T., Jennings C.D., Cibull M., et al. Effects of coumarin (1,2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies. Journal of Biological Response Modifiers 1989, 8(1):62-69.
18. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet 1995, 346:115.
19. McCarty M.F. Cimetidine as an adjuvant for allogeneic lymphocyte immunotherapy of cancer. Medical Hypotheses 1985, 17:155-156.
20. Morris D.L., Adams W.J. Cimetidine and colorectal cancer-old drug, new use. Nature Medicine 1995, 1:1243-1244.
21. Natori T., Sata M., Nagai R., Makuuchi M. Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomedicine and Pharmacotherapy 2005, 59:56-60.
22. Nefedova Y., Fishman M., Sherman S., Wang X., Beg A.A., Gabrilovich D.I. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Research 2007, 67:11021-11028.
23. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology 2009, 182(8):4499-4506.
24. Reynolds J.L., Akhter J., Morris D.L. In vitro effect of histamine and histamine HI and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines. Melanoma Research 1996, 6:95-99.
25. Rodriguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological Reviews 2008, 222:180-191.
26. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. Journal of Experimental Medicine 2005, 202:931-939.
27. Sagaster P., Micksche M., Flamm J., Ludwig H. Randomised study using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cell cancer. Annals of Oncology 1995, 6:999-1003.
28. Sahasrabudhe D.M., McCune C.S., O'Donnell R.W., Henshaw E.C. Inhibition of suppressor T lymphocytes (Ts) by cimetidine. Journal of Immunology 1987, 138:2760-2763.
29. Sasson A.R., Gamagami R., An Z., Wang X., Moossa A.R., Hoffman R.M. Cimetidine: an inhibitor or promoter of tumor growth. International Journal of Cancer 1999, 81:835-838.
30. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology 2006, 16(1):53-65.
31. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Research 2008, 68(13):5439-5449.
32. Sinha P., Chornoguz O., Clements V.K., Artemenko K.A., Zubarev R.A., Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 2011, 117(20):5381-5390.
33. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research 2005, 11:6713-6721.
34. Takahashi H.K., Watanabe T., Yokoyama A., Iwagaki H., Yoshino T., Tanaka N., et al. Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Molecular Pharmacology 2006, 70(2):450-453.
35. Talmadge J.E., Hood K.C., Zobel L.C., Shafer L.R., Coles M., Toth B. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. International Immunopharmacology 2007, 7:140-151.
36. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. Journal of Experimental Medicine 2003, 198:1741-1752.
37. Tonnesen H., Knigge U., Bulow S., Damm P., Fischerman K., Hesselfeldt P., et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988, 2:990-992.
38. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Research 2010, 70(8):3052-3061.
39. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Research 2005, 65:3044-3048.